How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

747 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Diagnosis and Treatment of Clinical Alzheimer’s-Type Dementia

Galantamine Versus Placebo and Galantamine Dose Comparisons 101 Key Messages 101 Eligible Studies 101 Baseline Study Characteristics 101 Outcomes 102 Variation in Outcomes by Participant Characteristics 103 Rivastigmine Versus Placebo 104 Key Messages 104 Eligible Studies 104 Baseline Study Characteristics 104 Outcomes 105 Variation in Outcomes by Participant Characteristics 108 Rivastigmine Dosage Comparisons 108 Key Messages 108 Eligible Studies 109 Baseline Study Characteristics 109 Outcomes 110 (...) Acids 121 Key Messages 121 Baseline Study Characteristics 121 Outcomes 121 Additional Supplements 122 Key Messages 122 Baseline Study Characteristics 123 Primary Outcomes 123 Chapter 8. Key Question 5: Prescription Drugs Versus Other Active Treatments for Cognition, Function, and Quality of Life 124 Prescription Drugs Versus Prescription Drugs 124 Galantamine Versus Donepezil 124 Memantine Versus Donepezil 126 Memantine Versus Antipsychotics 127 Supplements Versus Prescription Drugs 128 Key Messages

2020 Effective Health Care Program (AHRQ)

102. Donepezil

analysis). Secondary efficacy measures evaluated cognition, behavior, and function. The dual primary 2009 4. Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May (...) 2016 Share Save Guidance on donepezil ( Aricept ), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects

2018 Trip Latest and Greatest

103. Topiramate

with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician's suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous 2017 14. Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July (...) issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug

2018 Trip Latest and Greatest

104. Memantine

Guideline for Deprescribing Cholinesterase Inhibitors and Memantine . Sydney: The University of Sydney; 2018. The full guideline 2018 4. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 (...) Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new

2018 Trip Latest and Greatest

105. Drugs for Alzheimer's disease: finally delisted in France!

of copies of which have been downloaded from our website english.prescrire.org (1). In May 2018, France's Minister for Health took this negative harm-benefit balance into account. She decided that, from 1 August 2018, these drugs – donepezil, galantamine, rivastigmine and memantine – would be delisted, i.e. no longer reimbursed by the national health insurance system (2,3). This measure was not unexpected. In late 2016, the French Pharmacoeconomic (Transparency) Committee had concluded that these drugs

2018 Prescrire

106. Twenty-Five Pearls from 25 years (part 1)

provide harm data including serious adverse events that are not published elsewhere. 13 Donepezil has not been demonstrat- ed to improve outcomes of impor- tance to patients and caregivers (e.g. institutionalization or disability) Drugs for Alzheimer’s Disease [Apr-Aug 2005, issue 56]. Similarly, rivastigmine, galantamine and memantine have not been studied in terms of these important outcomes. It also concludes that acetylcholinesterase inhibitors cause gastrointestinal, muscular and other adverse

2019 Therapeutics Letter

112. Peri-operative care of people with dementia

and being in hospital. Key areas of supportconcern: 1 Knowingaboutthepersonwithdementia,forexample, making use of a ‘This is me’ or similar document (see ‘SourcesofFurtherInformation’); Table 2 Importantdruginteractionsbetweendementiamedicationanddrugsusedinanaesthesia. Half-life;hr Recommendation/effect Cholinesteraseinhibitors Galantamine 7 Discontinue a daybeforesurgery Rivastigmine 9 Discontinue a daybeforesurgery Donepezil 70 Notrecommended Memantine 60–100 Carewithketamine

2019 Association of Anaesthetists of GB and Ireland

115. Drugs to avoid

laxatives Moxifloxacin Bacterial infections Serious toxicity such as liver and cardiac disorders Ciprofloxacin, Ofloxacin Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Memantine Alzheimer’s and other dementias Minimal efficacy; disproportionate adverse effects such as severe vomiting and syncope Support from caregivers and family Alemtuzumab (Lemtrada), Natalizumab (Tysabri), Teriflunomide (Aubagio) Multiple sclerosis Disproportionate adverse effects such as infections and liver

2018 Therapeutics Letter

116. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine

that is characterised by a progressive loss in cognition, function and behaviour [1]. Worldwide, the number of people living with dementia is increasing every year [2]. There are currently two classes of medications available to treat the symptoms of dementia: cholinesterase inhibitors (ChEIs: donepezil, rivastigmine and galantamine) and the N- methyl-D-aspartate (NMDA) receptor antagonist, memantine [3]. These medications are not disease modifying, yet they can have important benefits to people with dementia (...) and harm to the individual. Thus, the purpose of this guideline is to assist healthcare professionals (particularly prescribers) to determine when it might be suitable to trial withdrawal of these medications for an individual. These recommendations only apply to individuals already taking one of the described medications (donepezil, rivastigmine, galantamine and/or memantine). The main points of this guideline are as follows: ? A proportion of people who have used these medications for over 12 months

2018 Clinical Practice Guidelines Portal

117. Dementia in Older People

but important part in management of dementia, providing symptomatic benefit with acetyl cholinesterase inhibitors (AChEI) (donepezil, rivastigmine and 8 galantamine) and memantine, which is a N- methyl-D-aspartate partial antagonist. AChEI have shown modest symptomatic improvement in 40-50% of people in cognitive function, global outcomes and activities of daily living. 61 Evidence suggests positive benefits for non-cognitive symptoms, especially apathy, depression and anxiety and improved function compared

2017 Australian and New Zealand Society for Geriatric Medicine

119. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine

and behavioural disturbances in dementia: carbamazepine (ESUOM40) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 21In 2006, NICE published a guideline on dementia: supporting people with dementia and their carers in health and social care (NICE guideline CG42), which has been incorporated into a NICE pathway. NICE guidance is also available on donepezil, galantamine, rivastigmine and memantine for the treatment

2015 National Institute for Health and Clinical Excellence - Advice

120. Parkinson's disease in adults.

of dementia with Lewy bodies. 6 At the time of publication (July 2017), rivastigmine capsules are the only treatment with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's for further information. 7

2017 National Guideline Clearinghouse (partial archive)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>